Clinical trial of autologous formalin‐fixed tumor vaccine for glioblastoma multiforme patients

• Published in: Cancer science Vol. 98; no. 8; pp. 1226 - 1233
• Main Authors: Ishikawa, Eiichi, Tsuboi, Koji, Yamamoto, Tetsuya, Muroi, Ai, Takano, Shingo, Enomoto, Takao, Matsumura, Akira, Ohno, Tadao
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.08.2007; Blackwell
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Brain Neoplasms - therapy; Cancer Vaccines - administration & dosage; Feasibility Studies; Female; Fixatives; Glioblastoma - therapy; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Medical sciences; Middle Aged; Neurology; Original; Pilot Projects; Predictive Value of Tests; Survival Rate; Treatment Outcome; Tumors; Tumors of the nervous system. Phacomatoses; Human; Malignant glioma; Nervous system diseases; Cancerology; Central nervous system disease; Clinical trial; Vaccine; Malignant tumor; Glioblastoma multiforme
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/j.1349-7006.2007.00518.x

A pilot study was performed to investigate the safety and feasibility of autologous formalin‐fixed tumor vaccines (AFTV) and the clinical responses to these vaccines by glioblastoma multiforme (GBM) patients. Twelve primary GBM patients were recruited. Eight had recurrent disease while four had been treated for primary disease but retained a visible tumor mass. AFTV were prepared from formalin‐fixed and/or paraffin‐embedded tumor tissue obtained upon surgery and premixed with original adjuvant materials. The patients were given three five‐site intradermal inoculations at weekly intervals. A delayed‐type hypersensitivity test was performed before and after each vaccination. In addition, the tumor tissues were subjected to immunohistochemical analysis to determine whether MIB‐1, p53, and major histocompatibility complex (MHC) class‐I complex expression could predict the response to the treatment. The treatment was well tolerated, with only local erythema, induration, and low‐grade fever being reported. Of the 12 patients, one showed a complete response, one showed a partial response, two showed minor responses, one had stable disease, and seven exhibited progressive disease. The median survival period was 10.7 months from the initiation of the AFTV treatment but three of the five responders survived for 20 months or more after AFTV inoculation. Low p53 and high MHC class‐I expression by the tumor may help predict the efficacy of this therapy. Thus, the AFTV is safe and feasible, and could significantly improve the outcome of GBM. Further clinical investigations to confirm this are highly desirable. (Cancer Sci 2007; 98: 1226–1233)